About: Molecular and serological assays for SARS-CoV-2: insights from genome and clinical characteristics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular and serological assays for SARS-CoV-2: insights from genome and clinical characteristics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular and serological assays for SARS-CoV-2: insights from genome and clinical characteristics
Creator	Zhang, Rui Li, Jinming Han, Dongsheng Shi, Jiping Zhang, Runling
Source	Medline; PMC
abstract	BACKGROUND: The ongoing outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a challenge for worldwide public health. A reliable laboratory assay is essential both to confirm suspected patients and to exclude patients infected with other respiratory viruses, thereby facilitating the control of global outbreak scenarios. CONTENT: In this review, we focus on the genomic, transmission and clinical characteristics of SARS-CoV-2, and comprehensively summarize the principles and related details of assays for SARS-CoV-2. We also explore the quality assurance measures for these assays. SUMMARY: SARS-CoV-2 has some unique gene sequences and specific transmission and clinical features that can inform the conduct of molecular and serological assays in many aspects, including the design of primers, the selection of specimens and testing strategies at different disease stages. Appropriate quality assurance measures for molecular and serological assays are needed to maintain testing proficiency. Because serological assays have the potential to identify later stages of the infection and to confirm highly suspected cases with negative molecular assay results, a combination of these two assays is needed to achieve a reliable capacity to detect SARS-CoV-2.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.1093/clinchem/hvaa122
bibo:pmid	32437513
has license	no-cc
sha1sum (hex)	b0c92e504c25e6505430e65553ee1e42e60830df
schema:url	https://doi.org/10.1093/clinchem/hvaa122
resource representing a document's title	Molecular and serological assays for SARS-CoV-2: insights from genome and clinical characteristics
has PubMed Central identifier	PMC7314174
has PubMed identifier	32437513
schema:publication	Clin Chem
resource representing a document's body	covid:b0c92e504c25e6505430e65553ee1e42e60830df#body_text
is schema:about of	named entity 'laboratory' named entity 'confirm' named entity 'assays' named entity 'suspected' named entity 'control' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'viruses' named entity 'public health' named entity 'ongoing outbreak' named entity 'genome' named entity 'serological' named entity 'nonstructural proteins' named entity 'false negatives' named entity 'false negatives' named entity 'peptide' named entity 'WHO' named entity 'radiography' named entity 'genomes' named entity 'false negative' named entity 'infection' named entity 'ORF' named entity 'Germany' named entity 'Roche Diagnostics' named entity 'viral load' named entity 'clinical testing' named entity 'high-throughput' named entity 'SARS-CoV' named entity 'epidemic' named entity 'CDC' named entity 'epidemiology' named entity 'IgG' named entity 'protein' named entity 'serological' named entity 'virus' named entity 'immune response' named entity 'ACE2' named entity 'IgA' named entity 'IgG' named entity 'cough' named entity 'nasopharyngeal swabs' named entity 'antigen' named entity 'viral shedding' named entity 'RT-PCR' named entity 'viral load' named entity 'SARS-CoV-2' named entity 'clinical laboratories' named entity 'RT-PCR' named entity 'global pandemic' named entity 'IgM' named entity 'Antibodies' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'alveolar' named entity 'antibody' named entity 'feces' named entity 'antibody' named entity 'nucleic acid test' named entity 'sputum' named entity 'False negative results' named entity 'proofreading' named entity 'laboratory testing' named entity 'nucleic acid' named entity 'clinical practice' named entity 'primers' named entity 'National Medical Products Administration' named entity 'IgM' named entity 'serological' named entity 'prognosis' named entity 'false negatives' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'IgM' named entity 'saliva' named entity 'epidemic' named entity 'sputum' named entity 'gene' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software